Trial Profile

A Multicenter, Randomized, Double Blinded, Placebo-controlled Clinical Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis by the AlcHepNet Consortium

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anakinra (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Zinc sulfate (Primary) ; Prednisone
Indications Alcoholic hepatitis
Focus Therapeutic Use
Acronyms AlcHepNet

14 Nov 2023 Results assessing the incidence of acute kidney injury in patients with severe alcohol-associated hepatitis presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
13 Sep 2022 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com